A multi-center, double blind, randomized, placebo-controlled, parallel group, flexible dose titration, add-on study of mecamylamine 5.0 to 10 mg, in the treatment of major depressive disorder with subjects who are partial or non- responders to citalopram therapy

Trial Profile

A multi-center, double blind, randomized, placebo-controlled, parallel group, flexible dose titration, add-on study of mecamylamine 5.0 to 10 mg, in the treatment of major depressive disorder with subjects who are partial or non- responders to citalopram therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Sep 2009

At a glance

  • Drugs Mecamylamine (Primary)
  • Indications Depression; Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Targacept
  • Most Recent Events

    • 13 Sep 2009 Results were presented at the 22nd Annual Congress of the European College of Neuropsychopharmacology (ECNP 2008)
    • 05 Feb 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top